Ignite Creation Date:
2024-05-06 @ 10:38 AM
Last Modification Date:
2024-10-26 @ 12:33 PM
Study NCT ID:
NCT03316469
Status:
UNKNOWN
Last Update Posted:
2018-06-27
First Post:
2017-10-10
Brief Title:
Anti-Mullerian Hormone as Predictor of Ovarian Responce to Clomiphene Citrate in PCOS
Sponsor:
Ain Shams University
Organization:
Ain Shams University
Study Overview
Official Title:
Circulating Anti-mullerian Hormone as Predictor of Ovarian Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome
Status:
UNKNOWN
Status Verified Date:
2018-06
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Polycystic ovary syndrome PCOS is found in 5 to 6 of women of reproductive age It affects womens reproductive capability thus patients have risks of infertility miscarriage and complicated pregnancy A study revealed that the prevalence of oligoovulation or anovulation in patients with PCOS ranged from 65 to 80 Anti-Mullerian Hormone AMH is an important regulator in the ovary that play a rule during development and function It is suspected to affect clomiphene citrate cc resistance In this study the investigator will assess the accuracy of AMH prediction of response to cc in women with PCOS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None